Shionogi's Anti-Obesity Drug S-2367 Phase IIb Shows Promising Results
This article was originally published in PharmAsia News
Shionogi announced May 13 that a Phase IIb analysis of anti-obesity drug S-2367 showed good results in both reduced calorie and low calorie tests. Following the analysis, Shionogi decided to continue the trials and plans to start Phase III trials during the second half of next year. Shionogi considers S-2367, which is being developed in the U.S., as one of its major products to expand overseas. Shionogi plans to obtain approval for the drug in 2011 and market it in 2013. The company is also looking for other companies to jointly develop and market the product. (Click here for more - Japanese language
You may also be interested in...
TOKYO - Osaka-based antibiotics manufacturer Shionogi reported positive results and "significant reduction in body weight" for its Phase II velneperit trial for obesity, but analysts were lukewarm about the results
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.